Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir Pediatric Formulations PK and Palatability Study
NCT04131556Phase 1Terminated
- Sponsor
- Takeda
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maribavir in cytomegalovirus infection (CMV), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 10, Time to Maximum Observed Plasma Concentration at Day 10 and 6 more. Started Oct 2019; status: terminated.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04131556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131556.